<DOC>
	<DOCNO>NCT01801163</DOCNO>
	<brief_summary>This research study radiation treatment call stereotactic body radiotherapy ( SBRT ) plus medicine call sorafenib . The purpose study evaluate safety SBRT plus Sorafenib see effect ( good bad ) treatment liver cancer .</brief_summary>
	<brief_title>A Phase Ib Study Stereotactic Body Radiotherapy ( SBRT ) Plus Sorafenib Patients With Unresectable Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>4.1.1Age ≥ 18 year . 4.1.2 Patients HCC without cirrhosis CTP class A ( maximum score 6 ) . 4.1.3 Patient must surgical candidate presentation . 4.1.4 Able undergo contrast enhance MRI primary tumor use liver MRI protocol . 4.1.5 Measurable disease per mRECIST criterion define lesion &gt; /=1cm show intratumoral arterial enhancement contrastenhanced CT MRI suitable repeat measurement . 4.1.6 Must evidence metastatic disease . 4.1.7 Karnofsky performance status &gt; /=70 % 4.1.8 Life expectancy ≥ 3 month determine treat physician . 4.1.9 If single tumor , maximum tumor diameter must &lt; /= 6 cm . 4.1.10 No three discrete liver lesion , overall sum diameter &lt; /= 6 cm . 4.1.11 None lesion treat close 0.5 cm wall stomach , duodenum , hepatic flexure colon . 4.1.12 Radiotherapy treatment planning confirm one following : One third uninvolved liver receive &lt; /=10 Gy At least 500 cc uninvolved liver receive &lt; /=7 Gy 4.1.13 Radiotherapy treatment planning confirms follow parameter normal tissue tolerance : Maximal cord dose : 600 cGy per fraction x3 total 18 Gy . Right kidney : &lt; 2/3 kidney volume receive &gt; 15 Gy total dose Left Kidney : &lt; 1/3 receives &gt; 15 Gy total dose . 4.1.14 Must fit stereotactic body immobilization device per institutional manufacturer guideline . 4.1.15 Patients must adequate liver function within 2 week study registration . Adequate liver function define follow : total bilirubin &lt; 3mg/dL albumin &gt; /= 2.5 g/dL INR &lt; /= 1.5 great mild elevation transaminase ( AST , ALT &lt; 5 x ULN ) 4.1.16 Patients must adequate renal function within 2 week study registration . Adequate renal function define one following : creatinine &lt; 1.8 mg/dl creatinine clearance ( CrCL ) &gt; /= 50 ml/min . 4.1.17 Adequate bone marrow reserve within 2 week study registration , define follow : ANC count &gt; /=1500 mm3 Platelets &gt; /=50,000/mm3 Hemoglobin &gt; 9g/dL 4.1.18 No history atherosclerotic coronary artery disease require bypass surgery , unless 1 ) bypass surgery occur 12 month prior enrollment , 2 ) disease stable ( consultation cardiologist ) . 4.1.19 Women must pregnant breastfeeding . The effect Sorafenib develop human fetus unknown . For reason radiation therapy Sorafenib use trial may teratogenic , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 4.1.20 No history HIV positivity , effect sorafenib combine radiation therapy patient HIV unknown . Patients know HIV risk factor ( determine treat physician ) eligible study without HIV test . 4.1.21 Must able provide write informed consent HIPAA authorization . 4.2.1 Medical history systemic lupus erythematous , rheumatoid arthritis , systemic sclerosis scleroderma . 4.2.2 Prior radiation therapy abdomen 4.2.3 Prior treatment Sorafenib Ras VEGF pathway inhibitor . 4.2.4 Minor surgical procedure ( e.g fine needle aspiration needle biopsy ) within 7 day study registration . 4.2.5 Major surgical procedure , significant traumatic injury , serious nonhealing wound , ulcer bone fracture within 21 day study registration ; investigator document adequate healing occur prior study registration . 4.2.6 Any follow within 6 month prior study drug administration : severe/unstable angina ( angina symptom rest ) , new onset angina ( begin within last 3 month ) myocardial infarction , congestive heart failure , cardiac ventricular arrhythmia require antiarrhythmic therapy . 4.2.7 History thrombotic embolic event cerebrovascular accident transient ischemic attack within past 6 month . 4.2.8 History aneurysm arteriovenous malformation . 4.2.9 Active , clinically serious infection &gt; /= CTCAE grade 2 . 4.2.10 Receipt investigational agent within 4 week study registration . 4.2.11 Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management 4.2.12 Pulmonary hemorrhage/bleeding event ≥CTCAE Grade 2 within 4 week study registration 4.2.13 Any hemorrhage/bleeding event include esophageal variceal bleed &gt; /= CTCAE Grade 3 within 4 week study registration . 4.2.14 Evidence history bleed diathesis coagulopathy 4.2.15 Chronic , daily treatment nonsteroidal antiinflammatory medication . ( Daily aspirin use permit ) 4.2.16 Use carbamazepine ( Carbatrol , Epitol , Equetro , Tegretol ) , rifabutin ( Mycobutin ) , rifampin/ rifampicin ( Rifadin , Rimactane ) , ritonavir ( Norvir ) . 4.2.17 Known suspect allergy Sorafenib agent give course trial . 4.2.18 Any condition impair patient 's ability swallow whole pill . 4.2.19 Any malabsorption problem would impair patient 's ability absorb oral medication . 4.2.20 Other severe , acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator , would make patient inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>